On July 31, 2019 TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration through our license to Santen Pharmaceutical Co. Ltd., and utilizing our product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., reported that it will report its second quarter 2019 financial and operating results after the close of U.S. financial markets on Wednesday, August 7, 2019 (Press release, Tracon Pharmaceuticals, JUL 31, 2019, View Source [SID1234538027]). In addition, management will host a conference call to provide an update on corporate activities and discuss the quarterly financial results.
Conference call and webcast:
Date: August 7, 2019
Time: 4:30 pm Eastern Time (1:30 pm Pacific Time)
Dial-in: (855) 779-9066 (Domestic) or (631) 485-4859 (International)
Via web: www.traconpharma.com; "Events and Presentations" section within the "Investors" section
A replay of the webcast will be available for 60 days on the website.